Business Wire

IPROOV

31.5.2022 14:02:08 CEST | Business Wire | Press release

Share
Finema Partners with iProov to Bring Enhanced Liveness Detection Capabilities to Identity Solution Onboarding

iProov , the world leader in biometric face authentication technology, announced today that Finema has chosen iProov’s Liveness Assurance™ technology to enhance the security of its Enterprise Decentralized Identity Platform.

Finema provides next-generation ID technology for corporate and government agencies that is easily interoperable and can be integrated with any existing identity platform, enabling fast-track adoption and competitive advantages.

iProov’s Liveness Assurance enables Finema to securely verify that an online user is the right person (not an imposter) and a real person (not a photo or mask being used in a presentation attack). In doing so, Finema can protect itself and its users by preventing stolen or fake identities being used for new account fraud.

“Finema is making major strides in the verifiable credentials space that signal a strengthening in the fight against online fraud and cybercrime,” said Andrew Bud, Founder and CEO of iProov. “To help combat online identity spoofing and theft, we need to ensure it stops before it starts at the account enrollment stage. We are thrilled to bring iProov’s secure and privacy-focused technology to Finema’s efforts to ID proof consumers.”

Finema’s user-centric and highly secure platform embodies Self-Sovereign Identity (SSI) principles to provide a superior solution for Identity and Access Management that includes Passwordless Authentication, Multi-factor Authentication, Digital Signature, Digital Consent, Digital ID Cards and Credentials.

“We are excited to enhance our decentralized identity product suite with iProov’s state-of-the-art Liveness Assurance technology,” said Pakorn Leesakul, CEO of Finema. “As identity fraud accounts for almost 1 trillion USD in losses every year, it is vital to form partnerships and invest in the best identity proofing technology that tackles the problem at its source.”

About Finema
Founded in 2017, Finema is the first decentralized digital identity company in Thailand. The company aims to change the world by means of decentralized digital identity technology. Finema helps corporates and government agencies construct their digital identity infrastructures by providing enterprise decentralized identity solutions that comprise a blockchain, an identity mapper, an e-ID wallet, and an identity proofing platform. The company is a major player in decentralized digital identity development. For more information, please visit https://finema.co or follow us on LinkedIn or Twitter .

About iProov
Launched in 2013, iProov is the world leader in online facial biometric authentication, working with governments, banks and other enterprises to securely verify customer identity. Used for effortless enrollment and authentication, customers include the U.S. Department of Homeland Security, the UK Home Office, the UK National Health Service (NHS), the Australian Taxation Office, GovTech Singapore, Rabobank, ING, and others. iProov’s technologies include Liveness Assurance™ and Genuine Presence Assurance® , which ensures that an online customer is the right person, a real person, and is authenticating right now. This protects against spoof attacks from photos, videos, masks and digital injection attacks and the emerging threat of deepfakes. iProov was recognized as a Gartner Cool Vendor 2020 in Identity Access Management & Fraud Detection. For more information, please see www.iproov.com or follow us on LinkedIn or Twitter .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Jeito Capital Hits Record $1.2 Billion (€1 Billion)1 Close for Jeito II Fund to Drive Breakthrough Therapeutic Innovation for Patients8.4.2026 08:15:00 CEST | Press release

This record closing is the largest raise ever achieved by a fully independent European fund dedicated to Biopharma, validating Jeito’s patient-driven investment strategy, its multidisciplinary, collaborative expertise spanning from science to commercialization of medicines, and value creationIn five years, Jeito Capital has tripled its assets under management to €1.6 billion, firmly establishing itself among the top-tier global Biopharma investorsJeito II will build on Jeito I’s proven and differentiated strategy, investing in the most promising clinical Biopharma companies which address unmet patient needs and severe diseases, accelerate breakthrough therapeutic innovation, and deliver transformative benefits for patientsThis fundraise represents significant momentum for European Biopharma, strengthening its financial firepower and expertise to develop the next generation of global champions Jeito Capital (“Jeito”), a global independent private equity fund dedicated to Biopharma, toda

Croma-Pharma Acquires Synocrom™ and Returns to Orthopaedics8.4.2026 07:00:00 CEST | Press release

Hyaluronic acid product for knee osteoarthritis available in the EU and Switzerland from May 2026 Croma-Pharma is returning to the orthopaedics market with the reacquisition of Synocrom™, a hyaluronic acid product for the treatment of knee osteoarthritis. A strategic return built on proven heritage With the reacquisition of Synocrom™, Croma-Pharma is re-entering orthopaedics and further broadening its portfolio in a field with strong historical roots for the company. Until 2014, Croma was active in orthopaedics, with Synocrom™ serving as a key pillar of its offering. Synocrom™ is not a new name in the market. During the period in which Croma actively marketed the product, it became one of the leading hyaluronic acid brands in Europe and ranked among the top brands in its category. Its return therefore represents more than a portfolio expansion: it marks the continuation of a successful orthopaedic legacy and reconnects Croma with an important part of its history. The reintroduction of

Murata Begins Mass Production of Seven Automotive MLCCs with World-leading Capacitance for Their Rated Voltage and Size, Supporting Stable Operation of In-vehicle Systems and Greater Design Flexibility8.4.2026 04:00:00 CEST | Press release

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has begun mass production of seven AEC-Q200-qualified multilayer ceramic capacitors (MLCCs) that achieve the world’s largest capacitance for a given rated voltage and size*, supporting stable operation of in-vehicle systems and greater design flexibility. Five parts in the GCM series are rated at 2.5-4 Vdc, targeting IC peripheral circuits in advanced driver assistance systems (ADAS) and autonomous driving (AD) applications. The remaining two MLCCs are rated at 25 Vdc for in-vehicle power line applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407486750/en/ [Murata Manufacturing Co., Ltd.] Seven automotive MLCCs In recent years, as ADAS and AD technologies advance, the number and performance level of systems installed in vehicles have continued to increase. As a result, demand for higher capacitance low-voltage MLCCs used around ICs has grown to e

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)7.4.2026 22:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seven newly hired non-executive employees. The equity awards were granted on April 1, 2026 and consisted of options to purchase an aggregate of 117,445 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 55,875 shares. The options have an exercise price per share equal to $5.62, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted s

SLB OneSubsea and Subsea7 Sign Collaboration Agreement with PETRONAS Suriname7.4.2026 22:05:00 CEST | Press release

Partnership enables early engagement to co-develop cost-effective solutions and accelerate subsea development in Suriname Global energy technology company SLB (NYSE: SLB) today announced the signing of a strategic collaboration agreement between PETRONAS Suriname E&P B.V. (“PETRONAS Suriname”), a subsidiary of PETRONAS and Subsea Integration Alliance, comprising SLB OneSubsea and Subsea7. This partnership aims to unlock resources in Suriname’s emerging frontier basin through innovative and cost-effective subsea solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331210557/en/ SLB OneSubsea has signed a strategic collaboration agreement between PETRONAS Suriname E&P B.V. (“PETRONAS Suriname”), a subsidiary of PETRONAS and Subsea Integration Alliance, comprising SLB OneSubsea and Subsea7. This partnership aims to unlock resources in Suriname’s emerging frontier basin through innovative and cost-effective subsea soluti

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye